Comparing Cyclerion Therapeutics (NASDAQ:CYCN) & Nutriband (NASDAQ:NTRB)

Nutriband (NASDAQ:NTRB) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Volatility & Risk

Nutriband has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500.

Profitability

This table compares Nutriband and Cyclerion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-103.36%	-91.38%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Institutional & Insider Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nutriband and Cyclerion Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Cyclerion Therapeutics	1	0	0	0	1.00

Earnings & Valuation

This table compares Nutriband and Cyclerion Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04 million	35.59	-$8.23 million	($0.53)	-11.26
Cyclerion Therapeutics	$2.07 million	9.61	-$3.53 million	($1.66)	-2.56

Cyclerion Therapeutics has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Cyclerion Therapeutics beats Nutriband on 7 of the 12 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.